Clinical Research
The Science Behind Eara
Our protocol is grounded in peer-reviewed clinical research. Here's the study, the data, and what it means for your tinnitus.
56.4%
THI Score Reduction
107
Trial Patients
660nm
Wavelength
p<0.0003
Statistical Significance
The Study
Panhóca et al. (2023) — University of São Paulo
In 2023, researchers at the University of São Paulo's Biophotonics Laboratory published a double-blind, randomised controlled trial evaluating 10 different treatment protocols across 107 tinnitus patients. The study was the first to demonstrate a positive treatment outcome for transmeatal low-level laser therapy (LLLT) that exceeded the placebo effect based on THI scores — in both idiopathic and refractory patients.
Patients were randomly divided into 10 groups, treated twice a week over 4 weeks (8 sessions total). Clinical evaluation was performed before treatment (T0), immediately after the 8th session (T1), and 15 days after complete cessation of treatment (T2) — using the Tinnitus Handicap Inventory (THI), the gold standard assessment tool for tinnitus severity.
📄 Download the Full Research Paper (PDF)Study Details
DOI: 10.3390/jpm13040581 — Open access, published 26 March 2023.
Treatment Groups
What They Tested
The study compared 10 distinct treatment approaches to determine which delivered the most significant and lasting reduction in tinnitus severity.
| Group | Treatment | THI Reduction (TO15) | p-value (T0 vs T2) |
|---|---|---|---|
| G1 | Placebo control (device off) | 40.1% | p < 0.001 |
| G2 | Vacuum therapy + transcochlear LLLT (660nm + 808nm, 6 min) | 41.0% | p < 0.01 |
| G3 | Vacuum therapy + LLLT + flunarizine dihydrochloride | 10.8% | Not significant |
| G4 | Flunarizine dihydrochloride alone (Vertix, 10mg/day) | 31.3% | p < 0.003 |
| G5 | Transcochlear LLLT + ultrasound | 6.4% | p < 0.05 |
| G6 | Transmeatal LLLT (660nm, 100mW, 6 min) | 16.8% | p < 0.02 |
| G7 | Transmeatal LLLT (660nm, 6 min) + Ginkgo biloba | 26.4% | p < 0.05 |
| G8 | Ginkgo biloba alone (120mg/day) | 26.1% | p < 0.002 |
| G9 | Transmeatal LLLT (660nm, 100mW, 15 min) | 56.4% | p < 0.0003 |
| G10 | Laser puncture (23 acupoints, 4J) | 44.7% | p < 0.002 |
TO15 = average normalised THI score reduction 15 days after complete treatment cessation. Higher is better. All values are raw percentages before placebo subtraction. Source: Panhóca et al., Figure 4 & Figure 5.
Key Findings
What the Data Shows
56.4% THI Score Reduction (G9)
Transmeatal LLLT at 660nm for 15 minutes achieved the highest THI reduction of any group — 16.3 percentage points above the placebo group's 40.1% reduction. This was the only transmeatal LLLT group to exceed placebo based on THI scores.
15 Minutes Dramatically Outperformed 6 Minutes
Increasing irradiation time from 6 min (G6: 16.8%) to 15 min (G9: 56.4%) produced a 39.6 percentage point improvement — demonstrating a strong dose-response relationship for transmeatal LLLT at 660nm.
Effects Continued After Treatment Stopped
G9 showed a positive lasting therapeutic effect (LTE15) at 15 days after complete treatment cessation. THI scores continued improving even with no treatment, indicating genuine cellular change rather than temporary masking.
Combination Therapies Showed Antagonistic Effects
Combining LLLT with vacuum therapy, ultrasound, Ginkgo biloba, or drugs produced short-term antagonistic effects — performing worse than LLLT alone. The study concluded that transmeatal LLLT alone (at sufficient duration) was the most effective approach.
Supplements and Drugs Underperformed
Ginkgo biloba alone (G8: 26.1%) and flunarizine alone (G4: 31.3%) both fell well below the placebo group's 40.1%. Neither supplement nor drug matched the placebo effect, let alone exceeded it.
First Positive Result for Idiopathic & Refractory Patients
The study was the first to demonstrate a treatment outcome exceeding placebo for transmeatal LLLT in both idiopathic patients (unknown cause) and refractory patients (no response to conventional therapy). Previous systematic reviews had found no significant effect.
The Mechanism
Why 660nm Red Light Through the Ear Canal Works
The paper describes the mechanism of action through photobiomodulation — the process by which light energy is absorbed by biological tissue and triggers cellular repair. Specifically for tinnitus, the proposed mechanism targets the cochlea, where damaged outer and inner hair cells (OHC and IHC) misfire and generate phantom auditory signals.
1
Light Absorption by Cytochrome c Oxidase
660nm photons delivered transmeatally (through the ear canal) reach cochlear tissue. The light is absorbed by cytochrome c oxidase (Cox) — the transmembrane protein complex in mitochondria responsible for photon absorption, leading to electronically excited states at the cellular level.
2
ATP Production Increases
Increased electron transport leads to increased adenosine triphosphate (ATP) production in irradiated tissue. Low levels of reactive oxygen species (ROS) are generated, activating transcription factors and inducing gene transcripts responsible for the beneficial effects of LLLT.
3
Microcirculation and Anti-Inflammatory Effects
LLLT accelerates microcirculation, changing hydrostatic pressure in capillaries with absorption of edema and inactivation of intermediate catabolites. This addresses one of the primary proposed causes of tinnitus: insufficient peripheral irrigation in tissues close to the inner ear.
4
Cellular Repair and Hair Cell Recovery
Repair mechanisms derive from increased blood flow and activation of mitochondria in the inner ear and hair cells, stimulating proliferation and collagen production. The analgesic action occurs through inhibition and release of endogenous analgesic substances by the central nervous system. Effects can persist up to 12 weeks after cessation of therapy.
"LP and Transmeatal LLLT can be promising alternative treatments for idiopathic and refractory tinnitus patients. Future studies should investigate the long-term effects of LLLT in tinnitus patients."
— Panhóca et al., Journal of Personalized Medicine, 2023How Eara Applies This
From Published Research to Daily Protocol
Eara Therabuds deliver the same core parameters as the winning treatment group (G9) in the São Paulo trial:
Same Wavelength Range
The study used 660nm red light. Eara Therabuds deliver 650nm — within the same therapeutic window for photobiomodulation of cochlear tissue. The paper notes that the 600–850nm range is sufficient for positive results.
Same Delivery Pathway
Transmeatal delivery — light passes through the ear canal directly toward the cochlea. This is the pathway that produced the only positive result exceeding placebo in the entire study. Transcochlear (post-auricular) delivery did not show the same effect.
Session Duration Aligned
The study's best results came from 15-minute sessions. The Eara protocol recommends 15-minute daily red light sessions to align with the parameters that produced the 56.4% THI reduction.
Extended Protocol for Greater Effect
The study ran 8 sessions over 4 weeks and noted effects continued to improve after treatment stopped. The Eara 90-Day Protocol extends this to daily use over 90 days, based on the finding that photobiomodulation can persist up to 12 weeks post-treatment.
Transparency
What the Research Supports — and What It Doesn't
What the evidence supports
Transmeatal LLLT at 660nm for 15 minutes produced a statistically significant reduction in tinnitus severity (p < 0.0003) that exceeded the placebo group. Effects persisted and continued improving 15 days after treatment ended. This was true for both idiopathic and refractory patients — the most difficult to treat.
Important context
The study involved 11 patients in the winning group (G9) over 4 weeks. The authors recommend larger-scale studies to validate results. The placebo group also showed a 40.1% THI reduction, meaning some improvement is expected regardless of treatment. Eara did not fund, design, or participate in this study. Individual results will vary.
Study Limitations
What the Researchers Noted
The paper acknowledges several limitations, and we believe transparency about these strengthens rather than weakens the evidence:
The sample size (10-11 patients per group) is typical for early-stage RCTs but too small to be confirmatory for the entire population. Patients with cofounding factors (age, gender, hearing loss) could not be perfectly homogenised across groups. The researchers explicitly recommend larger-scale studies using the same G9 protocol parameters. Long-term effects beyond 15 days post-treatment remain to be studied, though LLLT photobiomodulation has been reported to potentially persist up to 12 weeks after cessation.
We share these limitations because we believe the tinnitus community deserves honesty. This study is a strong early signal, not a final answer. It's the reason we offer a money-back guarantee — try the protocol, measure your own results.
Start the 90-Day Protocol
Same wavelength range. Same delivery pathway. 90 days to decide.
Start Your Protocol$547 · Free shipping · 30-day money-back guarantee
Disclaimer: The Eara Therabuds are a consumer wellness device, not a medical device. The clinical study referenced (Panhóca, V.H. et al., "Effects of Red and Infrared Laser Therapy in Patients with Tinnitus: A Double-Blind, Clinical, Randomized Controlled Study Combining Light with Ultrasound, Drugs and Vacuum Therapy," J. Pers. Med. 2023, 13, 581) was conducted independently at the University of São Paulo. Eara did not fund, design, or participate in this study. The study used laboratory-grade photobiomodulation equipment at 660nm. Eara Therabuds deliver 650nm red light through the same transmeatal delivery pathway. The study's winning group (G9) included 11 patients over 4 weeks; larger studies are recommended by the authors. Individual results may vary. This product is not intended to diagnose, treat, cure, or prevent any disease. If you have concerns about tinnitus, consult a qualified healthcare professional.
Full citation: Panhóca, V.H.; de Aquino Junior, A.E.; de Souza, V.B.; Ferreira, S.A.; Ferreira, L.T.; de Oliveira Souza, K.J.; Tamae, P.E.; Saito Nogueira, M.; Bagnato, V.S. J. Pers. Med. 2023, 13, 581. DOI: 10.3390/jpm13040581